Home/Resources/BPC-157 vs TB-500
At a glance
- BPC-157 — a synthetic 15-amino-acid peptide (“stable gastric pentadecapeptide”) studied in animal tissue-repair models.
- TB-500 — a synthetic fragment related to thymosin beta-4 (Tβ4), a naturally occurring peptide studied for cell migration and angiogenesis in animal models.
- They are structurally distinct with different proposed mechanisms in the preclinical literature.
- Both are research compounds. Neither is approved for human use, and no efficacy is claimed here.
BPC-157 and TB-500 come up together constantly in research discussion, usually framed as rivals. In reality they’re different molecules with different origins and different proposed roles in animal-model studies. This page lays out what the preclinical literature actually describes — and, just as importantly, what it does not.
What BPC-157 is
BPC-157 is a synthetic peptide of 15 amino acids, sometimes described as a “stable gastric pentadecapeptide.” In preclinical work it has been investigated in animal models of tendon, ligament, and other soft-tissue repair. For example, rat-model studies have examined BPC-157 in the context of tendon-to-bone and ligament healing.[1][2] Review literature has discussed its proposed cytoprotective role.[3]
These are animal-model and review findings. They describe what has been observed or proposed in research settings, not outcomes in humans.
What TB-500 is
TB-500 is a synthetic peptide related to thymosin beta-4 (Tβ4), a small, naturally occurring peptide. In preclinical research, thymosin beta-4 has been studied for its roles in cell migration, angiogenesis, and wound-healing processes in animal and laboratory models — for instance, work reporting accelerated wound healing[4] and studies on its actin-binding site and angiogenesis.[5] Review literature has summarized its modes of action and research potential.[6]
Again, these reflect preclinical research. They are not evidence of safety or effectiveness in humans.
How they compare
| Attribute | BPC-157 | TB-500 |
|---|---|---|
| Origin | Synthetic peptide; sequence derived from a gastric protein fragment | Synthetic fragment related to thymosin beta-4, a naturally occurring peptide |
| Structure | 15 amino acids (pentadecapeptide) | Short fragment associated with the Tβ4 actin-binding region |
| Research focus (preclinical) | Tendon, ligament, and soft-tissue repair in animal models | Cell migration, angiogenesis, and wound-healing processes in animal/lab models |
| Proposed mechanism (as discussed in literature) | Cytoprotective and tissue-repair pathways | Actin regulation, cell migration, and angiogenic signaling |
| Regulatory status | Not approved for human use — research compound | Not approved for human use — research compound |
| At Astra Peptides | Available as a standalone research compound | Available in combination research products (e.g. BPC-157 + TB-500) |
The honest summary: these are different peptides studied along partly overlapping research themes (tissue repair) but with distinct structures and proposed mechanisms. Comparisons that frame one as strictly “better” than the other go beyond what the preclinical evidence supports.
Research compounds at Astra Peptides
If you’re sourcing either compound for research, every batch ships with a Certificate of Analysis — read it in the COA Library before you buy, and see how to read a COA.
Research use only
This comparison is educational and reflects preclinical, animal-model and review literature. All Astra Peptides products are sold strictly for laboratory and research use only (RUO); they are not pharmaceuticals and are not intended for human or veterinary use. Nothing on this page is a medical claim or dosing guidance, and no statement should be read as evidence of safety or effectiveness in humans.Common questions
What is the difference between BPC-157 and TB-500 in research?
BPC-157 is a synthetic 15-amino-acid peptide (a stable gastric pentadecapeptide) studied in preclinical animal models for tissue-repair pathways. TB-500 is a synthetic fragment related to thymosin beta-4, a naturally occurring peptide studied in preclinical models for cell migration, angiogenesis, and wound-healing processes. Both are research compounds and neither is approved for human use.
Are BPC-157 and TB-500 studied together?
They are frequently compared in research discussion because both appear in preclinical tissue-repair literature, but they are structurally distinct peptides with different proposed mechanisms in animal models. Any combined use is purely a research-design consideration; no efficacy or human-use conclusions are implied.
Does Astra Peptides sell BPC-157 and TB-500?
Astra Peptides offers BPC-157 as a standalone research compound, and TB-500 is available in combination research products such as BPC-157 + TB-500. Browse the full catalog to see current availability. All products are research use only.
References
- Krivic A, et al. (2006). Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: promoted tendon-to-bone healing and opposed corticosteroid aggravation. J Orthop Res. PubMed 16583442
- Cerovecki T, et al. (2010). Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat. J Orthop Res. PubMed 20225319
- Sikiric P, et al. (2010). Revised Robert’s cytoprotection and adaptive cytoprotection and stable gastric pentadecapeptide BPC 157. Curr Pharm Des. PubMed 20166993
- Malinda KM, et al. (1999). Thymosin beta4 accelerates wound healing. J Invest Dermatol. PubMed 10469335
- Philp D, et al. (2003). The actin binding site on thymosin beta4 promotes angiogenesis. FASEB J. PubMed 14500546
- Smart N, et al. (2007). Thymosin beta4 and angiogenesis: modes of action and therapeutic potential. Angiogenesis. PubMed 17632766
